HC Wainwright & Co. Maintains Neutral on Kyverna Therapeutics, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Neutral rating on Kyverna Therapeutics (NASDAQ:KYTX) and lowered the price target from $8 to $7.
August 15, 2024 | 11:27 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. has maintained a Neutral rating on Kyverna Therapeutics and lowered the price target from $8 to $7.
The lowered price target from $8 to $7 suggests a less optimistic outlook for Kyverna Therapeutics, which could negatively impact investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100